KALA BIO, Inc. Common Stock (KALA) Stock Price

KALAStock

$0.19−99.72%52W

Market Cap$3.67M

P/E—

PEG Ratio—

Div yield—

Beta-2.43

KALA Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-108.22%

Price vs S&P 500 (4W)-64.76%

VGM Score46.95

Book Value / Share (Quarterly)$0.47

P/TBV (Annual)0.88x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-1.03

Price vs S&P 500 (YTD)-111.24%

Gross Margin (TTM)30.96%

Net Profit Margin (TTM)-1383.48%

EPS (TTM)$-72.45

10-Day Avg Trading Volume0.67M

EPS Excl Extra (TTM)$-72.45

EPS (Annual)$-10.26

ROI (Annual)-91.19%

Gross Margin (Annual)34.19%

Net Profit Margin (5Y Avg)-7795.15%

Cash / Share (Quarterly)$0.37

ROA (Last FY)-70.29%

EBITD / Share (TTM)$-4.87

ROE (5Y Avg)-413.54%

Operating Margin (TTM)-1261.57%

Cash Flow / Share (Annual)$-242.90

P/B Ratio0.41x

P/B Ratio (Quarterly)3.56x

Net Income / Employee (Annual)$-6,500,000

EV / Revenue (TTM)0.60x

Net Interest Coverage (TTM)-12.60x

ROA (TTM)-70.23%

EPS Incl Extra (Annual)$-10.26

Current Ratio (Annual)3.11x

Quick Ratio (Quarterly)4.84x

3-Month Avg Trading Volume1.12M

52-Week Price Return-99.72%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$4.17

P/S Ratio (Annual)0.94x

Asset Turnover (Annual)0.04x

52-Week High$95.50

Operating Margin (5Y Avg)-7404.03%

EPS Excl Extra (Annual)$-10.26

CapEx CAGR (5Y)-62.19%

Tangible BV CAGR (5Y)-26.70%

26-Week Price Return-98.32%

Quick Ratio (Annual)3.02x

13-Week Price Return-75.52%

Total Debt / Equity (Annual)2.47x

Current Ratio (Quarterly)6.88x

Enterprise Value$3.44M

Asset Turnover (TTM)0.05x

Book Value / Share Growth (5Y)19.00%

Revenue / Employee (Annual)$0

Inventory Turnover (Annual)0.60x

Pretax Margin (Annual)-1152.19%

Cash / Share (Annual)$420.14

3-Month Return Std Dev120.01%

Net Income / Employee (TTM)$-1,680,000

ROE (Last FY)-316.25%

Net Interest Coverage (Annual)-11.63x

EPS Basic Excl Extra (Annual)$-10.26

Receivables Turnover (TTM)0.00x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-72.45

Receivables Turnover (Annual)0.00x

ROI (TTM)-28.16%

P/S Ratio (TTM)0.64x

Pretax Margin (5Y Avg)-7795.15%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$11.12

Price vs S&P 500 (52W)-115.26%

Year-to-Date Return-99.32%

5-Day Price Return-32.18%

EPS Normalized (Annual)$-10.26

ROA (5Y Avg)-69.35%

Net Profit Margin (Annual)-1152.19%

Month-to-Date Return-55.77%

Cash Flow / Share (TTM)$-21.40

EBITD / Share (Annual)$-10.72

Operating Margin (Annual)-958.61%

LT Debt / Equity (Annual)1.63x

ROI (5Y Avg)-94.88%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-72.45

P/TBV (Quarterly)1.49x

P/B Ratio (Annual)3.43x

Inventory Turnover (TTM)0.60x

Pretax Margin (TTM)-1383.48%

Book Value / Share (Annual)$101.23

Price vs S&P 500 (13W)-78.21%

Beta-2.43x

Revenue / Share (TTM)$0.00

ROE (TTM)-28.16%

52-Week Low$0.11

vGradeA

mGradeF

vgmGradeC

KALA Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q3 2025	Nov 19, 2025	-$50.50	-$53.50	-5.94%(-$3.00)
Q2 2025	Aug 8, 2025	-$102.00	-$65.94	+35.36%(+$36.06)
Q1 2025	May 14, 2025	-$127.00	-$50.66	+60.11%(+$76.34)
Q4 2024	Mar 31, 2025	-$123.50	-$61.58	+50.14%(+$61.92)

KALA Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

2.17

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
KALAKALA BIO, Inc. Common Stock	A	—	F	0.6x	—	31.0%	—	$0.19
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About KALA BIO, Inc. Common Stock

Kala Bio is a clinical-stage biopharmaceutical company developing cell-derived therapies for rare eye diseases. The company's lead candidate, KPI-012, is a human mesenchymal stem cell product designed to restore corneal healing and treat severe retinal degenerative diseases including Retinitis Pigmentosa and Stargardt Disease. KPI-012 leverages multiple therapeutic factors including growth factors and neuroprotective proteins to address unmet needs in vision-threatening conditions.